Furthermore, our study used the anti-VEGF antibody bevacizumab to specifically block VEGF function in 5×FAD mice at 4 months of age and demonstrated beneficial and significant effects of reducing amyloid-related brain pathology, improving vascular integrity and function, and rescuing memory performance. The gene discussed is VEGFA; the disease is amyloidosis.